Edward V Loftus Jr

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences
    Edward V Loftus
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 126:1504-17. 2004
  2. ncbi request reprint Colorectal cancer prognosis among patients with inflammatory bowel disease
    Thierry Delaunoit
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 4:335-42. 2006
  3. pmc Safety of TNF-α inhibitors during IBD pregnancy: a systematic review
    Ole Haagen Nielsen
    Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
    BMC Med 11:174. 2013
  4. pmc Incidence of spondyloarthropathy in patients with Crohn's disease: a population-based study
    Raina Shivashankar
    Department of Medicine, Division of Gastroenterology and Hepatology and Division of Rheumatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Rheumatol 39:2148-52. 2012
  5. pmc Experiences of patients with chronic gastrointestinal conditions: in their own words
    Jennifer B McCormick
    Division of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Health Qual Life Outcomes 10:25. 2012
  6. doi request reprint Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn's disease in the United States
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    J Crohns Colitis 5:550-4. 2011
  7. ncbi request reprint Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000
    Conor G Loftus
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 13:254-61. 2007
  8. doi request reprint Increased risks of developing anxiety and depression in young patients with Crohn's disease
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 106:1670-7. 2011
  9. doi request reprint Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 17:127-40. 2011
  10. doi request reprint Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease
    Edward V Loftus
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur J Gastroenterol Hepatol 21:1302-9. 2009

Detail Information

Publications110 found, 100 shown here

  1. ncbi request reprint Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences
    Edward V Loftus
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 126:1504-17. 2004
    ..Additional epidemiologic studies to define better the burden of illness, explore the mechanism of association with environmental factors, and identify new risk factors are needed...
  2. ncbi request reprint Colorectal cancer prognosis among patients with inflammatory bowel disease
    Thierry Delaunoit
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 4:335-42. 2006
    ..The objectives of this study were to describe the clinicopathologic features of IBD-associated CRC and to compare survival rates between patients with IBD-associated CRC and patients with sporadic CRC...
  3. pmc Safety of TNF-α inhibitors during IBD pregnancy: a systematic review
    Ole Haagen Nielsen
    Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
    BMC Med 11:174. 2013
    ..Because this chronic intestinal disorder often affects women of fertile age, it is essential to assess the effect of biologics on pregnancy outcome...
  4. pmc Incidence of spondyloarthropathy in patients with Crohn's disease: a population-based study
    Raina Shivashankar
    Department of Medicine, Division of Gastroenterology and Hepatology and Division of Rheumatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Rheumatol 39:2148-52. 2012
    ..We assessed the cumulative incidence and clinical spectrum of SpA in patients with Crohn's disease (CD) in a population-based cohort...
  5. pmc Experiences of patients with chronic gastrointestinal conditions: in their own words
    Jennifer B McCormick
    Division of Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Health Qual Life Outcomes 10:25. 2012
    ..The symptoms are well-documented and can be debilitating. How these chronic gastrointestinal (GI) conditions impact the daily lives of those afflicted is not well documented, especially from a patient's perspective...
  6. doi request reprint Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn's disease in the United States
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    J Crohns Colitis 5:550-4. 2011
    ..To determine the real-world dosage pattern of adalimumab and predictors for weekly dosing in Crohn's disease (CD)...
  7. ncbi request reprint Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000
    Conor G Loftus
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 13:254-61. 2007
    ..We sought to update the incidence and prevalence of these conditions in our region through 2000...
  8. doi request reprint Increased risks of developing anxiety and depression in young patients with Crohn's disease
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 106:1670-7. 2011
    ..This retrospective cohort study compared the risks of developing anxiety disorders and depression and incidences of psychotropic medication use between young CD patients and matched CD-free controls...
  9. doi request reprint Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 17:127-40. 2011
    ..A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking...
  10. doi request reprint Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease
    Edward V Loftus
    Miles and Shirley Fiterman Center for Digestive Diseases, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur J Gastroenterol Hepatol 21:1302-9. 2009
    ..This study evaluated the cost-effectiveness of adalimumab versus conventional, nonbiologic pharmacotherapies in the maintenance of Crohn's disease...
  11. ncbi request reprint Does monitoring prevent cancer in inflammatory bowel disease?
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, S W, Rochester, MN 55905, USA
    J Clin Gastroenterol 36:S79-83; discussion S94-6. 2003
    ..The benefits of frequent physician visits and compliance with medication regimens with regard to reduction in colorectal cancer risk are also reviewed...
  12. doi request reprint Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 15:566-75. 2009
    ..We describe colectomy subtypes, follow-up surgical and diagnostic procedures, complications, and direct medical charges occurring within 180 days of colectomy among privately insured patients with ulcerative colitis (UC)...
  13. pmc Crohn's disease: why the disparity in mortality?
    E V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, SW Rochester, MN 55905, USA
    Gut 55:447-9. 2006
  14. ncbi request reprint Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 35:517-31. 2006
    ....
  15. ncbi request reprint Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Clin Gastroenterol Hepatol 1:465-73. 2003
    ..Osteopenia is common in patients with ulcerative colitis (UC), but less is known about fracture risk. Previously we were unable to demonstrate increased fractures in a population-based cohort with Crohn's disease...
  16. ncbi request reprint Management of extraintestinal manifestations and other complications of inflammatory bowel disease
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 6:506-13. 2004
    ..A randomized trial of ursodeoxycholic acid in PSC showed decreased risk of colorectal neoplasia in patients receiving the drug relative to those on placebo...
  17. pmc PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
    E V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Gut 54:91-6. 2005
    ..Inflammatory bowel disease associated with primary sclerosing cholangitis (PSC-IBD) may have a high prevalence of rectal sparing, backwash ileitis, and colorectal neoplasia...
  18. ncbi request reprint Hunting for the owl's eye in acute severe colitis: the role of cytomegalovirus
    E V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Liver Dis 36:803-5. 2004
  19. ncbi request reprint Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis
    E V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 19:179-89. 2004
    ..To determine whether there is a difference in short-term adverse events in patients with ulcerative colitis treated with mesalazine, olsalazine or balsalazide...
  20. ncbi request reprint Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 123:468-75. 2002
    ..Osteoporosis is common in patients with Crohn's disease, but less is known about their risk of actual fractures...
  21. ncbi request reprint Epidemiology of inflammatory bowel disease
    Edward V Loftus
    Department of Medicine, Mayo Medical School, Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 31:1-20. 2002
    ..Regardless of the exact prevalence, the burden of disease in North America and Europe is significant. Studying the patterns of geographic variation and age and gender distribution may yield important clues to the cause of IBD...
  22. ncbi request reprint A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies
    Edward V Loftus
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Inflamm Bowel Dis 12:1107-13. 2006
    ..Development of such a therapy would, therefore, potentially improve both patient compliance and overall treatment success...
  23. ncbi request reprint The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review
    E V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 16:51-60. 2002
    ..To quantify, through systematic review, the epidemiology and natural history of Crohn's disease in North America...
  24. ncbi request reprint The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study
    W A Faubion
    Division of Gastroenterology and Hepatology, Section of Biostatistics, Mayo Clinic and Foundation, 200 1st Street, Rochester, MN 55905, USA
    Gastroenterology 121:255-60. 2001
    ..CONCLUSIONS: Most patients with Crohn's disease and ulcerative colitis initially respond to corticosteroids. At 1 year, 32% of patients with Crohn's disease and 48% with ulcerative colitis are corticosteroid free without operation...
  25. pmc Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
    P W Lowry
    Division of Gastroenterology, Division of Clinical Pharmacology, Department of Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
    Gut 49:656-64. 2001
    ....
  26. ncbi request reprint Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort
    M D Silverstein
    Division of Area General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Gastroenterology 117:49-57. 1999
    ..The aim of this study was to describe the lifetime clinical course and costs of Crohn's disease in a 24-year population-based inception cohort of patients with Crohn's disease in Olmsted County, Minnesota...
  27. ncbi request reprint Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease
    W J Tremaine
    Division of Gastroenterology and Hepatology, Fiterman Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 25:1435-41. 2007
    ..There is conflicting data regarding the response to medical and surgical therapy for inflammatory bowel disease with respect to age at disease onset...
  28. ncbi request reprint Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease
    W J Sandborn
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 7:192-201. 2001
    ..Likewise, the sensitivity and diagnostic usefulness of these assays in patients with inflammatory bowel disease (IBD) in the community is unknown...
  29. ncbi request reprint Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA
    Gastroenterology 130:1941-9. 2006
    ..The presence of postinflammatory pseudopolyps and use of other anti-inflammatory medications may be important variables that influence risk, but data are sparse...
  30. ncbi request reprint Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine
    D S Pardi
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Gastroenterology 120:1483-4. 2001
    ..Some patients do not tolerate corticosteroid side effects, and a small subset are dependent on or refractory to corticosteroids. We report our experience with azathioprine and 6-mercaptopurine in patients with microscopic colitis...
  31. ncbi request reprint Crohn's disease of the esophagus: clinical features and outcomes
    G A Decker
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 7:113-9. 2001
    ..Immune modifier therapy should be considered for steroid-dependent and steroid-resistant cases...
  32. ncbi request reprint Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease
    Craig A Solem
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Inflamm Bowel Dis 11:707-12. 2005
    ..We sought to examine the relationship between C-reactive protein (CRP) and clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease (IBD)...
  33. ncbi request reprint Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy
    Jean Frederic Colombel
    Division of Gastroenterology and Hepatology, Division of Colorectal Surgery, and Section of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 99:878-83. 2004
    ..The aim was to determine whether the use of steroids, immunosuppressive agents, or infliximab prior to abdominal surgery for Crohn's disease is associated with an increased rate of early postoperative complications...
  34. doi request reprint Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease
    J B Kisiel
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
    Aliment Pharmacol Ther 37:546-54. 2013
    ..Current approaches to the detection of colorectal neoplasia associated with inflammatory bowel disease (IBD-CRN) are suboptimal...
  35. ncbi request reprint Cigarette smoking and celiac sprue: a case-control study
    A H Patel
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:2388-91. 2001
    ..3). In all, 34% of cases were former smokers versus 28% of controls, yielding an odds ratio of 1.6 (95% CI = 0.8-3.2). CONCLUSION: This case-control study was unable to detect an association between cigarette smoking and celiac disease...
  36. pmc Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein
    J F Colombel
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Gut 55:1561-7. 2006
    ..Few studies have correlated computed tomography (CT) enterography findings with endoscopic severity and C reactive protein (CRP) concentrations...
  37. ncbi request reprint Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis
    Chelliah R Selvasekar
    Division of Colon and Rectal Surgery, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Am Coll Surg 204:956-62; discussion 962-3. 2007
    ..Infliximab (IFX), an antitumor necrosis factor-alpha antibody, has demonstrated efficacy in medical management of CUC. The aim of this study is to determine if IFX before IPAA impacts short-term outcomes...
  38. doi request reprint Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience
    S V Kane
    Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 18:2203-8. 2012
    ..Natalizumab, a monoclonal antibody to alpha-4 integrin approved for CD, has demonstrated efficacy in randomized clinical trials. We describe our experience with natalizumab in clinical practice at Mayo Clinic Rochester...
  39. ncbi request reprint Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
    E Ricart
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:722-9. 2001
    ..A total of 23 patients were continued on infliximab as maintenance treatment. CONCLUSIONS: This study provides additional evidence that infliximab is safe and beneficial in clinical practice for refractory Crohn's disease...
  40. doi request reprint MHC Class II alleles in ulcerative colitis-associated colorectal cancer
    M M Garrity-Park
    Division of Experimental Pathology and Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Gut 58:1226-33. 2009
    ..Furthermore, since methylation of the Class II transactivator (CIITA) gene may silence HLA expression in tumours, we correlated HLA allele frequencies with CIITA gene methylation and HLA-DR expression...
  41. ncbi request reprint Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with psc
    W A Faubion
    Department of Internal Medicine and Pediatrics, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55902, USA
    J Pediatr Gastroenterol Nutr 33:296-300. 2001
    ....
  42. doi request reprint Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 103:1737-45. 2008
    ..We sought to describe the types of colectomy, follow-up surgical/diagnostic procedures, and complications occurring within 180 days of colectomy in a population of privately insured individuals with ulcerative colitis (UC)...
  43. doi request reprint Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease
    Waqqas Afif
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 105:1133-9. 2010
    ..Human anti-chimeric antibodies (HACAs) and subtherapeutic infliximab concentrations are associated with decreased duration of response. We evaluated the clinical utility of measuring HACA and infliximab concentrations...
  44. ncbi request reprint Clinical perspectives in Crohn's disease. Objective measures of disease activity: alternatives to symptom indices
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Rev Gastroenterol Disord 7:S8-S16. 2007
    ....
  45. doi request reprint Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
    A B Mohabbat
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 36:569-74. 2012
    ..Ulcerative colitis (UC) and Crohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver transplantation (OLT) despite post-transplantation immunosuppressive therapy...
  46. ncbi request reprint Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial
    W J Sandborn
    Mayo Clinic, Rochester, MN, USA
    Aliment Pharmacol Ther 17:1355-64. 2003
    ..Repifermin (keratinocyte growth factor-2) has been shown to reduce inflammation in animal models of colitis...
  47. ncbi request reprint A prospective cohort study of practice guidelines in inflammatory bowel disease
    W J Tremaine
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 96:2401-6. 2001
    ..The MPGS is a tool that can be used in day-to-day management of IBD patients...
  48. pmc Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease
    W J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Gut 53:780-2. 2004
    ..Patients with moderate to severely active Crohn's disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin's lymphoma...
  49. doi request reprint Disease perceptions among people with Crohn's disease
    Sunanda V Kane
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 14:1097-101. 2008
    ..We sought to characterize CD patient perceptions of both overall disease course and current symptomatology based on an objective symptom scale and to explore the relationship between perceptions and current symptoms...
  50. pmc The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota
    Darrell S Pardi
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905, USA
    Gut 56:504-8. 2007
    ..Although the epidemiology of microscopic colitis has been described in Europe, no such data exist from North America. We studied the incidence, prevalence and temporal trends of microscopic colitis in a geographically defined US population...
  51. doi request reprint Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer
    Megan M Garrity-Park
    Division of Experimental Pathology and Lab Medicine, Mayo Clinic, Garrity Park, 200 First Street SW, Stabile 2 50, Rochester, MN 55905, USA
    Am J Gastroenterol 105:1610-9. 2010
    ..Surveillance in this at-risk population remains challenging. We assessed the methylation status of genes in the non-neoplastic mucosa of UC-CRC patients and controls to identify potential biomarkers of CRC...
  52. ncbi request reprint Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography
    Fargol Booya
    Department of Radiology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Radiology 241:787-95. 2006
    ..Mural attenuation for different bowel loops was compared by using a Student t test, with kappa statistics used to measure interobserver agreement and Pearson correleation coefficients used to compare visual and quantitative measures...
  53. ncbi request reprint Internet use by patients in an inflammatory bowel disease specialty clinic
    Robert R Cima
    Division of Colon and Rectal Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Inflamm Bowel Dis 13:1266-70. 2007
    ..Our aim was to evaluate internet use to gather general health- and disease-specific information in patients presenting to an IBD clinic...
  54. ncbi request reprint Management of Crohn's disease of the ileoanal pouch with infliximab
    Jean Frederic Colombel
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 98:2239-44. 2003
    ..The occurrence of Crohn's disease (CD) in a patient with an ileal-pouch anastomosis (IPAA) often results in severe morbidity and significant chance of reservoir loss. We report our experience of the use of infliximab in these patients...
  55. doi request reprint Computerized tomography enterography and its role in small-bowel imaging
    Joel G Fletcher
    Department of Radiology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    Clin Gastroenterol Hepatol 6:283-9. 2008
    ..The purpose of this article is to summarize how the examination is performed, and to specify appropriate indications and alternatives, performance characteristics, and anticipated future developments...
  56. ncbi request reprint Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community
    Kiran Bambha
    Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 125:1364-9. 2003
    ..The epidemiology of primary sclerosing cholangitis (PSC) in the United States is unknown. We report the incidence, clinical spectrum, and outcomes of PSC in Olmsted County, Minnesota...
  57. ncbi request reprint Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis
    Darrell S Pardi
    Division of Gastroenterology and Hepatology and Division of Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Gastroenterology 124:889-93. 2003
    ..We sought to evaluate the effect of UDCA on colorectal neoplasia in a group of patients with UC and PSC enrolled in a randomized, placebo-controlled trial...
  58. ncbi request reprint Evolving diagnostic modalities in inflammatory bowel disease
    Jonathan A Leighton
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Curr Gastroenterol Rep 7:467-74. 2005
    ..Finally, positron emission tomography is an investigative tool for inflammatory bowel disease that may also aid in the detection of inflammation in these diseases...
  59. ncbi request reprint Treatment of inflammatory bowel disease in the elderly: an update
    Darrell S Pardi
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Drugs Aging 19:355-63. 2002
    ..Controlled trials and clinical experience have shown that infliximab is a significant addition to the therapeutic armamentarium for patients with Crohn's disease...
  60. doi request reprint Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases
    D A Katzka
    Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Pharmacol Ther 92:306-20. 2012
    ..Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes...
  61. pmc Cyclosporin for refractory ulcerative colitis
    C G Loftus
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gut 52:172-3. 2003
  62. doi request reprint Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial
    Edward V Loftus
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 103:3132-41. 2008
    ..We evaluated the effects of adalimumab maintenance therapy on health-related quality of life (HRQOL) in patients with moderate to severe Crohn's disease...
  63. doi request reprint The natural history of adult Crohn's disease in population-based cohorts
    Laurent Peyrin-Biroulet
    Division of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 105:289-97. 2010
    ..This comprehensive review summarizes our current knowledge of the natural history of Crohn's disease in adults as reported in population-based studies that include long-term follow-up results...
  64. doi request reprint An update on the epidemiology of inflammatory bowel disease in Asia
    Kelvin T Thia
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 103:3167-82. 2008
    ....
  65. ncbi request reprint Abnormal hepatic biochemistries in patients with inflammatory bowel disease
    Flavia D Mendes
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 102:344-50. 2007
    ..We determined the prevalence of abnormal hepatic biochemistries and chronic liver disease in a cohort of IBD patients, and we compared patients with normal and abnormal liver biochemistries...
  66. ncbi request reprint Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Am J Gastroenterol 100:1435-8. 2005
  67. doi request reprint Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer
    Megan M Garrity-Park
    Division of Experimental Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Am J Gastroenterol 103:407-15. 2008
    ..Because UC patients are at increased risk for developing colorectal cancer (CRC), we investigated if there was an association between SNPs in the promoter of the TNF-alpha gene and UC-CRC...
  68. pmc Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota
    Stefan D Holubar
    Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Colon Rectum 52:1815-23. 2009
    ..This study was designed to test the hypothesis that patients undergoing definitive surgery for chronic ulcerative colitis have reduced direct medical costs after, as compared with before, total proctocolectomy...
  69. ncbi request reprint Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease
    Murat Toruner
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 11:428-34. 2005
    ..We sought to determine if any endoscopic factors during surveillance colonoscopy were associated with the diagnosis of colorectal dysplasia before the development of cancer...
  70. ncbi request reprint Safety of infliximab and other biologic agents in the inflammatory bowel diseases
    Jagadeshwar G Reddy
    General Internal Medicine, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Gastroenterol Clin North Am 35:837-55. 2006
    ..Proper selection of candidates for anti-TNF-alpha therapy is critical in maintaining a proper benefit-to-risk ratio...
  71. pmc Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort
    Kelvin T Thia
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 139:1147-55. 2010
    ..We sought to assess the evolution of Crohn's disease behavior in an American population-based cohort...
  72. doi request reprint Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography
    David H Bruining
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 14:1701-6. 2008
    ..We also sought to examine the percentage of clinically significant new noninflammatory bowel disease (IBD) related findings in these patients...
  73. doi request reprint Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial
    Craig A Solem
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastrointest Endosc 68:255-66. 2008
    ..With the introduction of new techniques to image the small bowel, there remains uncertainty about their role for diagnosing Crohn's disease...
  74. pmc Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease
    Joanna M Peloquin
    Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 103:2015-22. 2008
    ..However, the extent of radiation exposure in these patients is unknown...
  75. ncbi request reprint Microscopic colitis is not associated with cholecystectomy or appendectomy
    Aran W Laing
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Inflamm Bowel Dis 12:708-11. 2006
    ..The aim of this study was to assess cholecystectomy and appendectomy as potential risk factors for the development of microscopic colitis in a nested case-control study...
  76. ncbi request reprint Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease
    Uma Mahadevan
    Division of Gastroenterology and Hepatology, University of California, San Francisco, 55905, USA
    Am J Gastroenterol 97:910-4. 2002
    ..Cyclooxygenase-2 inhibitors have fewer GI side effects than traditional NSAIDs in unselected patients. We report the safety of these agents in patients with IBD...
  77. doi request reprint Inflammatory bowel disease in the setting of autoimmune pancreatitis
    Karthik Ravi
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Inflamm Bowel Dis 15:1326-30. 2009
    ..Despite scattered case reports, the prevalence of inflammatory bowel disease (IBD) in patients with autoimmune pancreatitis (AIP) is unknown. We sought to better characterize the putative association between the conditions...
  78. doi request reprint Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease
    Hassan A Siddiki
    Department of Radiology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA
    AJR Am J Roentgenol 193:113-21. 2009
    ....
  79. doi request reprint Assessment of appropriateness of indications for CT enterography in younger patients
    Luis S Guimaraes
    Department of Radiology, Mayo Clinic, Rochester, Minnestota 55905, USA
    Inflamm Bowel Dis 16:226-32. 2010
    ..We sought to determine the appropriateness of CTEs based on clinical indication in patients < or =35 years old, and the potential impact of evolution of practice to alternative magnetic resonance enterography (MRE)...
  80. ncbi request reprint Diagnostic advances in inflammatory bowel disease (imaging and laboratory)
    Maria E Moscandrew
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 11:488-95. 2009
    ..Magnetic resonance enterography is a radiation-free cross-sectional imaging alternative that is comparable to CT enterography in diagnostic accuracy...
  81. ncbi request reprint Images in clinical medicine. Fistulizing Crohn's disease
    William Sanchez
    Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 347:416. 2002
  82. ncbi request reprint The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota
    David A Schwartz
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 122:875-80. 2002
    ..Little is known about the cumulative incidence and natural history of fistulas in Crohn's disease in the community...
  83. doi request reprint Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease
    Kelvin T Thia
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Am J Gastroenterol 103:3123-31. 2008
    ..The Crohn's Disease Activity Index (CDAI) is used to judge efficacy in clinical trials. We explored the effect of CDAI response definitions for induction on study efficiency...
  84. ncbi request reprint A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis
    Jeanne Tung
    Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Inflamm Bowel Dis 12:1093-100. 2006
    ..The goal of this study was to examine the 1-year outcome after the first course of systemic corticosteroids in an inception cohort of pediatric patients with inflammatory bowel disease...
  85. ncbi request reprint Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation
    Kale D Bodily
    Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Radiology 238:505-16. 2006
    ....
  86. ncbi request reprint Evolving diagnostic strategies for inflammatory bowel disease
    David H Bruining
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 8:478-85. 2006
    ..Magnetic resonance enterography uses principles similar to those for CT enterography, and early results are encouraging...
  87. ncbi request reprint Biologic therapy in Crohn's disease: review of the evidence
    Edward V Loftus
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Rev Gastroenterol Disord 7:S3-12. 2007
    ..Adverse events associated with anti-TNF-a therapy, including infection, infusion reactions, autoimmunity, risk of malignancy, and neurologic events, are reviewed...
  88. ncbi request reprint An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street NW, Rochester, MN 55905, USA
    Am J Gastroenterol 99:1984-9. 2004
    ....
  89. ncbi request reprint Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study
    Elena Ricart
    Inflammatory Bowel Disease Clinic, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 10:207-14. 2004
    ..We sought to determine the association between EIMs and AD in patients with first-degree familial IBD and sporadic IBD...
  90. ncbi request reprint Small intestinal adenocarcinoma in Crohn's disease: a case-control study
    Craig A Solem
    Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Inflamm Bowel Dis 10:32-5. 2004
    ..Small bowel adenocarcinoma is an uncommon complication of Crohn's disease. We sought to describe the clinical features, outcomes, and risk factors of small bowel adenocarcinoma in Crohn's disease...
  91. ncbi request reprint Current and future diagnostic approaches: from serologies to imaging
    David H Bruining
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
    Curr Gastroenterol Rep 9:489-96. 2007
    ..These newer modalities add to the armamentarium clinicians can use for evaluation of IBD...
  92. ncbi request reprint The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients
    Jean Frederic Colombel
    Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
    Gastroenterology 126:19-31. 2004
    ..The aim of this study was to evaluate the short- and long-term safety of infliximab in patients with Crohn's disease in clinical practice...
  93. doi request reprint Meta-analysis: serological markers and the risk of acute and chronic pouchitis
    S Singh
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Aliment Pharmacol Ther 37:867-75. 2013
    ..Serological markers such as anti-neutrophil cytoplasmic antibody (ANCA) and anti-Saccharomyces cerevisiae antibody (ASCA) may be associated with pouchitis after ileal pouch-anal anastomosis (IPAA)...
  94. ncbi request reprint The natural history of perianal Crohn's disease
    S B Ingle
    Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dig Liver Dis 39:963-9. 2007
    ..Cancer, a rare complication of perianal disease, must be suspected when lesions persist despite therapy...
  95. ncbi request reprint Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota
    Tine Jess
    Department of Medical Gastroenterology, Herlev University Hospital, Herlev, Denmark
    Gastroenterology 130:1039-46. 2006
    ..We estimated the risk for small-bowel and colorectal cancer in a population-based cohort of 692 inflammatory bowel disease patients from Olmsted County, Minnesota, from 1940 to 2001...
  96. ncbi request reprint Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates
    Pia Munkholm
    Herlev University Hospital, Copenhagen, Denmark
    Digestion 73:11-9. 2006
    ..However, definitive proof from prospective clinical trials is not available...
  97. ncbi request reprint The fate of low grade dysplasia in ulcerative colitis
    Thomas A Ullman
    The Dr Henry D Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, New York, New York, USA
    Am J Gastroenterol 97:922-7. 2002
    ..The optimal strategy for the management of definite low grade dysplasia (LGD) detected in surveillance in ulcerative colitis (UC) is unknown, because the natural history of LGD has not been well described...
  98. ncbi request reprint N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis
    Elena Ricart
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Gastroenterol 97:1763-8. 2002
    ..We determined the association between NAT1 genotype and response to mesalamine and sulfasalazine, as well as between NAT2 genotype and toxicity to sulfasalazine, in a population-based cohort of patients with ulcerative colitis...
  99. ncbi request reprint Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement
    Miguel Regueiro
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Inflamm Bowel Dis 12:972-8. 2006
    ..Those who have ongoing signs and symptoms of ulcerative proctitis and left-sided ulcerative colitis despite maximal medical therapy require a proctocolectomy...
  100. ncbi request reprint Constrictive pericarditis in chronic ulcerative colitis
    Amy S Oxentenko
    Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    J Clin Gastroenterol 34:247-51. 2002
    ..Although our patient may have had IBD-associated constrictive pericarditis, her mesalamine use raises the possibility of a drug-induced constrictive pericarditis...
  101. ncbi request reprint Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota
    Tine Jess
    Department of Medical Gastroenterology, Herlev University Hospital, Herlev, Denmark
    Inflamm Bowel Dis 12:669-76. 2006
    ....